During the corresponding time, Lifecore Biomedical Inc saw a revenue deteriorated by -35.54 % year on year, While revenue at the Lifecore Biomedical Inc 's corporate clients
Lifecore Biomedical Inc's Comment on Sales, Marketing and Customers
Lifecore Biomedical, Inc. provides injectable products for a range of medical conditions and procedures, including ophthalmic and orthopedic applications. The company develops highly viscous, non-HA-based sterile injectable products and offers product development services such as analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. Manufacturing is conducted at three cGMP facilities producing FDA-approved commercial drug and device products. Lifecore operates semi-automated Restricted Access Barrier Systems and fully automated aseptic filling lines with isolators to support aseptic processing of synthetic and biologic drug products. The company holds certifications from regulatory agencies in Europe, Japan, Brazil, and ISO. Lifecore's markets include contract development and manufacturing organization (CDMO) services for synthetic and biologic drug products, focusing on injectable products for ophthalmic and orthopedic medical conditions and procedures. Customers named in filings include 22NW, LP and BMO Harris Bank N.A.
Lifecore Biomedical and Nirsum Labs Collaborate on Development of Innovative Opioid Use Disorder Treatment Lifecore Biomedical, a renowned contract development and manufacturing organization (CDMO), has recently been selected by Nirsum Labs to provide comprehensive development and manufacturing services for NRS-033, a novel treatment aimed at addressing opioid use disorder. This partnership signifies a crucial step in the planned Phase 2 clinical trial of the innovative therapeutic candidate.The collaboration between Lifecore Biomedical and Nirsum Labs is set to encompass a series of critical development services. This includes technology transfer, which involves the systematic process of transferring knowle...
New York, September 10, 2024 - Bragar Eagel and Squire, P.C. a law firm recognized nationwide for its expertise in shareholder rights, has issued a reminder to investors regarding pending class action lawsuits on behalf of stockholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYSE: SPIR), Oddity Tech (NASDAQ: ODD), and Arbor Realty Trust, Inc. (NYSE: ABR). The firm encourages stockholders who have been affected to contact them to serve as lead plaintiffs before the deadlines pass. Lifecore Biomedical, Inc. (NASDAQ: LFCR) Lifecore Biomedical, Inc. a company engaged in the development and manufacturing of complex biopharmaceutical products, is among the entities facing a class action la...
Lifecore Biomedical Faces a Class Action Lawsuit: Implications for Investors and the Biopharmaceutical Sector In a significant legal development within the biopharmaceutical sector, Lifecore Biomedical, Inc. (NASDAQ: LFCR) has become the target of a class action lawsuit filed in the United States District Court for the District of Minnesota. The announcement, made by the Pomerantz Law Firm on August 3, 2024, signals serious concerns regarding the company s compliance with federal securities laws and could have far-reaching implications for both current investors and the company s future operations. The Case Overview The class action lawsuit is notably structured to benefit a wide range of stakeholders, enc...
In recent developments, Rosen Law Firm, a prominent global investor rights law firm, has initiated an investigation into potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. (formerly known as Landec Corporation). The investigation stems from allegations suggesting that Lifecore Biomedical may have disseminated materially misleading business information to the investing public. This has raised concerns within the pharmaceutical industry and the wider investment community, necessitating a thorough examination of the issue.Background:Lifecore Biomedical Inc., a renowned pharmaceutical company listed on the NASDAQ under the symbols LFCR and LNDC, has gained significant attention fro...
In a significant move aimed at solidifying its longstanding partnership, Lifecore Biomedical has recently entered into a series of commercial agreements with Alcon, a leading global eye care company. These agreements entail new, mutually beneficial 8-year commercial manufacturing arrangements that are set to further enhance both companies market position and product offerings.Recognized as a renowned provider of contract manufacturing solutions for complex biomaterials and high-value medical devices, Lifecore Biomedical has consistently demonstrated its commitment to delivering exceptional quality and innovative solutions. The company s track record of excellence has earned them a reputation as a trusted pa...
Lifecore Biomedical Inc’s Comment on Sales, Marketing and Customers
Lifecore Biomedical, Inc. provides injectable products for a range of medical conditions and procedures, including ophthalmic and orthopedic applications. The company develops highly viscous, non-HA-based sterile injectable products and offers product development services such as analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. Manufacturing is conducted at three cGMP facilities producing FDA-approved commercial drug and device products. Lifecore operates semi-automated Restricted Access Barrier Systems and fully automated aseptic filling lines with isolators to support aseptic processing of synthetic and biologic drug products. The company holds certifications from regulatory agencies in Europe, Japan, Brazil, and ISO. Lifecore's markets include contract development and manufacturing organization (CDMO) services for synthetic and biologic drug products, focusing on injectable products for ophthalmic and orthopedic medical conditions and procedures. Customers named in filings include 22NW, LP and BMO Harris Bank N.A.
Sources:
Lifecore Biomedical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lifecore Biomedical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lifecore Biomedical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
103.25 %